Close

TKT R438W

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

T cell immunity directed against tumor-encoded amino acid substitutions occurs in some melanoma patients. This implicates missense mutations as a source of patient-specific neoantigens. TKT R438W is characterized as subdominant antigens as T cell immunity required peptide vaccination and these neoantigens are processed and presented from endogenously expressed protein.
  • TCR Vector Products

  • TCR Cell Products

  • TCR Viral Particles

Loading...
  • TCR Clone:
  • Host Species:
  • Epitope:
  • Allele:
  • Vector Type:
CAT Product Name Target Species TCR Clone Host Species Epitope Allele Vector Type Inquiry & Datasheet
TCR-YC1189 Human anti-TKT R438W T cell receptor (MEL21), pCDTCR1 MEL21 Human AMFWSVPTV HLA-A*02:01 Lentiviral vector   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.